Testosterone Suits Soar Past 2,500 As Legal Milestone Looms for AbbVie
Sales of AbbVie's embattled testosterone drug AndroGel fell in what was otherwise a strong quarter for the company. Now AbbVie is facing the selection of the bellwether cases to be tried next year involving men who believe they were harmed by the gel.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Arlene Weintraub Source Type: news